Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma

Saved in:

Bibliographic Details
Main Authors:	Anna Marina Liberati, Umberto Vitolo, Antonio Palumbo, Agostino Cortelezzi
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Series:	Advances in Hematology
Online Access:	http://dx.doi.org/10.1155/2013/812605
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
by: Roberta Martiniani, et al.
Published: (2012-01-01)

Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
by: Barbara Lupo, et al.
Published: (2012-01-01)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
by: Agostino Cortelezzi, et al.
Published: (2012-01-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide in Diffuse Large B-Cell Lymphomas
by: Annalisa Chiappella, et al.
Published: (2012-01-01)

IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA
by: Zeynep Kürüm, et al.
Published: (2025-07-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
by: Bo Yang, et al.
Published: (2013-01-01)

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01)

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
by: Donna Reece, et al.
Published: (2012-01-01)

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
by: Matthew K. Adams, et al.
Published: (2019-01-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
by: S. A. Tuchman, et al.
Published: (2012-01-01)

Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells
by: Takumi Yamamoto, et al.
Published: (2024-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

A response of rituximab plus lenalidomide therapy in patients with post-transplant lymphoproliferative disease and methotrexate-related lymphoproliferative disorder in the central nervous system: a case report
by: Hanguo Guo, et al.
Published: (2025-05-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone
by: Takuto Tachita, et al.
Published: (2024-07-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
by: Benjamin J. Lee, et al.
Published: (2025-06-01)

SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
by: Ioana Martac, et al.
Published: (2024-12-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder
by: Poornima Ramadas, et al.
Published: (2021-01-01)

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
by: Seunghee Kim-Schulze, et al.
Published: (2024-04-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

Posttransplant Lymphoproliferative Disorders
by: Hazem A. H. Ibrahim, et al.
Published: (2012-01-01)

HHVs AND LYMPHOPROLIFERATIVE DISORDERS
by: C Quadrelli, et al.
Published: (2011-10-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

TREATMENT MANAGEMENT IN MULTIPLE MYELOMA WITH RENAL DISORDER
by: Meryem Sener
Published: (2025-07-01)

Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Influence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT
by: II Kostroma, et al.
Published: (2018-04-01)

Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US
by: Niodita Gupta-Werner, et al.
Published: (2025-07-01)